Compare GWH & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWH | EVAX |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 25.9M |
| IPO Year | 2020 | 2020 |
| Metric | GWH | EVAX |
|---|---|---|
| Price | $0.34 | $3.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $2.25 | ★ $11.67 |
| AVG Volume (30 Days) | ★ 1.1M | 200.0K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,583,000.00 | N/A |
| Revenue This Year | $33.99 | N/A |
| Revenue Next Year | $1,328.57 | $328.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.31 | $2.71 |
| 52 Week High | $13.87 | $12.15 |
| Indicator | GWH | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 30.20 | 49.66 |
| Support Level | $0.34 | $2.91 |
| Resistance Level | $1.09 | $3.62 |
| Average True Range (ATR) | 0.07 | 0.26 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 9.22 | 34.57 |
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. It develops and manufactures long-duration energy storage systems based on iron flow battery technology. The company's batteries use earth-abundant materials, including iron, salt, and water, and are designed for high cycle life and recyclability. It operates as a single business operating segment, which includes all activities related to the design, engineering, and manufacturing of the company's long duration energy storage products. The company's revenue is derived from the sale of its energy storage products and from service contracts.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.